International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 3, Issue 7 | Research Article | Open Access DOI
Narjis Malik*
Narjis Malik1*,Hafsa Manzoor2, Hafiz SohailAshraf3 ,Saud Ghazi4, Shamsher5, Muhammad Haris6
1Medical Officer, Shalamar medical and dental college
2Medical Officer, Shalamar medical and dental college
3Medical officer, King Edward Medical University
4Consultant Medical Oncologist, Shifa International Hospital Islamabad
5Consultant Oncologist ShifaInternational Hospital
6King Edward Medical University
*Correspondence to: Narjis Malik
Fulltext PDFProstate overgrowth and urinary symptoms go hand In hand and pose a major threat to the male community of the world. The case study we will discuss is related to benign prostate hyperplasia and effect of somatostatin analogues (STSAs).This report shows a 73 year old male with Gastrointestinal neuroendocrine tumors who concomitantly was diagnosed with BPH and was given Octreotide/somatostatin LAR which led to decrease in both urinary tract symptoms and prostate volume. This report further discuss the underlying mechanism of these drugs and highlight the potential of this drug to be drug of choice or adjunct therapy. Limitations are highlighted as well bit the promising role is to be investigated as well.
cBenign prostatic hyperplasia; BPH; Case report
Hafiz Sohail Ashraf, Narjis Malik, HafsaManzoor, Saud Ghazi, Shamsher, Muhammad Haris. Use of Somatostatin Analogues (STSAs) in the Treatment of Benign Prostatic Hyperplasia (BPH), A Case Report. IntClincMedCaseRepJour. 2024;3(7):1-8.